Efficacy and safety of prolonged use of aspirin or rivaroxaban after surgery for hip fractures
Not Applicable
Completed
- Conditions
- Prevention of venous thromboembolism after hip fracture surgeryCirculatory System
- Registration Number
- ISRCTN76129839
- Lead Sponsor
- Department of Orthopedic Surgery, West China Hospital, Sichuan University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 390
Inclusion Criteria
1. Hip fracture who were diagnosed by X-ray and/or computed tomography.
Exclusion Criteria
1. Lower extremity DVT confirmed by preoperative ultrasonography
2. History of thromboembolic disease and undergoing anticoagulant therapy
3. Presence of hemorrhagic diseases and/or a major bleeding history
4. Severe liver or kidney diseases
5. Coagulation disorders
6. Allergy to enoxaparin, aspirin, or rivaroxaban
7. Platelet count less than 100*10^9 cells/L
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Adjudicated venous thromboembolism, which was defined as deep vein thrombosis involving the inferior vena cava to popliteal vein or pulmonary embolism. Ultrasonography of the lower extremity vein is a routine examination. All patients had to be examined before and after surgery. Pulmonary embolism was confirmed by computed tomographic pulmonary angiography, when the patient's symptoms are suspected to be a pulmonary embolism.<br> 2. The primary safety outcome was bleeding, including major or clinically relevant nonmajor bleeding, according to Anderson’s criteria. Patients were followed for 90 days regarding venous thromboembolism and bleeding complications.<br>
- Secondary Outcome Measures
Name Time Method <br> Incidence of health issues in the 90 days following the intervention:<br> 1. Death<br> 2. Myocardial infarction<br> 3. Stroke<br> 4. Wound infection.<br>